Reported results
- Collaboration revenue was $30.3 million for the three months ended September 30, 2026, compared to $76.3 million for the three months ended September 30, 2025.
- Net income from continuing operations was $3.9 million for the three months ended September 30, 2026, compared to $56.3 million for the three months ended September 30, 2025.
- General and administrative expenses from continuing operations were $11.6 million for the three months ended September 30, 2026, compared to $1.1 million for the three months ended September 30, 2025.
- Research and development expenses from continuing operations were a negative $1.3 million for the three months ended September 30, 2026, compared to a negative $2.0 million for the three months ended September 30, 2025.
- Cash, cash equivalents and investments totaled $153.0 million as of September 30, 2026.
Guidance
- Anaptys continues to expect to achieve >$390 million in annualized Jemperli royalties payable to Anaptys as early as 2029 at GSK’s peak monotherapy sales guidance of >$2.7 billion.
- Anaptys anticipates paydown of the remaining ~$270 million non-recourse debt monetization in calendar H2 2027.
Notes
The separation of AnaptysBio and First Tracks Biotherapeutics was completed on April 20, 2026; beginning in the second quarter of 2026, AnaptysBio reclassified historical First Tracks Biotherapeutics, Inc. related assets, liabilities and expenses as discontinued operations.
Price and volatility reaction
The stock moved -3.2% on the print. No front-expiry chain was on file, so there is no straddle expected move.
| Measure | Value | Basis |
|---|---|---|
| Close before release | 47.77 | 2026-11-12 |
| Close after release | 46.25 | 2026-11-13 |
| Realised move | -3.2% | close to close |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
